A Phase 1, Multicenter, Open-label, Multiple Dose escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects with Advanced Cancers with HER2 Expression

  • Markman, Ben (Primary Chief Investigator (PCI))
  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/17/MonH/354
Monash Health Ref: RES-17-0000-531A
StatusActive
Effective start/end date16/11/1815/11/24

Keywords

  • clinical trial
  • treatment efficacy
  • advanced cancer